Study Finds PSA Below 0.2 ng/mL Cuts Death Risk 54% in Metastatic Prostate Cancer
Updated
Updated · Inside Precision Medicine · Aug 7
Study Finds PSA Below 0.2 ng/mL Cuts Death Risk 54% in Metastatic Prostate Cancer
3 articles · Updated · Inside Precision Medicine · Aug 7
Summary
4,890 U.S. veterans with metastatic castration-sensitive prostate cancer lived significantly longer when PSA fell below 0.2 ng/mL within nine months of starting treatment.
A 54% lower risk of death was tied to that absolute PSA threshold, while a 90% PSA drop alone showed no significant survival or progression benefit if levels stayed above 0.2 ng/mL.
44% of patients reached the under-0.2 target, versus 74% who achieved at least a 90% decline, suggesting many clinicians may be relying on a weaker benchmark.
ADT plus an androgen receptor pathway inhibitor made patients 71% more likely to hit the target than ADT alone, though only about half on combination therapy did so.
The retrospective CANCER study supports using 0.2 ng/mL to guide earlier treatment intensification or possible de-escalation, even as ongoing trials test those strategies.